Healthcare Industry News: xTAG
News Release - February 20, 2008
Luminex Corporation Places 5,000th InstrumentAUSTIN, Texas--(HSMN NewsFeed)--Luminex Corporation (NASDAQ: LMNX ), the worldwide leader in multiplexed solutions, today announced that it has recently delivered its 5,000th instrument to Beaumont Hospital in Royal Oak, Michigan. Beaumont Hospital, Royal Oak, will use the Luminex® 200™ instrument to perform the FDA-cleared Luminex xTAG™ Respiratory Viral Panel (RVP) to assist doctors in diagnosing respiratory infections quickly.
“Multiplexing is, in many ways, the future of molecular diagnostics," said Dr. Domnita Crisan, medical director of the molecular pathology laboratory at Beaumont Hospital, Royal Oak. “The ability to run many tests at once provides us faster, more clinically relevant results. The Luminex instrument is an important multiplexing tool for us. It provides accurate results very quickly and efficiently, and is easy to use.”
The Luminex analyzer is a unique instrument that can be used across the continuum of science and healthcare – from basic research to clinical diagnostics. The instrument can be found in pharmaceutical and academic research laboratories, clinical reference laboratories and hospitals of all sizes.
“Delivering our 5,000th instrument is an important milestone for Luminex as our proprietary xMAP® Technology, driven by the test menu expansion of our partners and the Luminex Assay Group, continues to gain momentum in the marketplace,” said Patrick J. Balthrop, president and chief executive officer of Luminex Corporation. “Our product portfolio now includes a diversity of applications, such as the newly launched xTAG RVP and FlexmiR™ microRNA assays. These tests, combined with our partners’ developments in protein research, immunodiagnostics, HLA and other areas, have led to record instrument sales for Luminex. We look forward to working with our partners and end-users to continue finding new ways our xMAP Technology can advance science and healthcare.”
Luminex instruments are flexible analyzers based on the principles of three-dimensional bead arrays. Due to the enhanced liquid kinetics of the microspheres in solution, these arrays offer superior uniformity and faster reaction times than standard two-dimensional planar arrays. Proprietary xMAP Technology from Luminex also provides the laboratory the power of multiplexing and the ability to produce superior results in much less time than traditional methods like ELISA or real-time PCR. Luminex develops and manufactures state-of-the-art assay products, and licenses its instruments and bead-based xMAP technology to market-leading companies in clinical diagnostics and biological research. Assays from Luminex and its partners deliver fast and cost-effective results for nucleic acid assays, receptor-ligand assays, immunoassays and enzymatic assays.
About Luminex Corporation
Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The Company's xMAP® multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets. The Company's xMAP technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP technology can be obtained at www.luminexcorp.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.